Raising Money in Biotechnology: From Discovery to IPO

Harvard Extension School

BIOT E-122

Section 1

CRN 17558

View Course Details
Biotechnology (biotech) is one of the most capital-intensive and high-risk industries in the world, requiring founders and leaders to navigate complex funding pathways across scientific, regulatory, and commercial milestones. This course provides a comprehensive, real-world understanding of how biotech companies raise capital, from early discovery and seed funding to venture capital, strategic partnerships, and public markets. Students explore the full financing lifecycle of biotech ventures, including non-dilutive funding, angel and venture capital, corporate partnerships, venture philanthropy, private equity, and initial public offerings (IPOs). The course emphasizes how scientific breakthroughs, clinical milestones, regulatory strategy, and market positioning influence valuation, investor interest, and fundraising outcomes. Through case studies of emerging and established biotech companies, students analyze investor decision-making, deal structures, term sheets, and the strategic alignment between founders and capital providers. The course also examines the evolving landscape of biotech finance, including the role of contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), artificial intelligence (AI)-driven drug discovery, platform companies, and global capital markets. Students gain insights into how venture firms, institutional investors, and corporate venture arms evaluate opportunities, manage risk, and support portfolio growth. By the end of the course, students understand the biotech funding ecosystem and major sources of capital; evaluate financing strategies across the lifecycle of a biotech company; analyze term sheets, valuation methods, and deal structures; develop investor-ready narratives and pitch strategies; identify key milestones that drive funding and valuation; assess risks, governance, and ethical considerations in biotech investing; and understand exit pathways, including mergers and acquisitions (M&A), partnerships, and IPOs. This course is designed for scientists, entrepreneurs, investors, and professionals seeking a deep, practical understanding of biotech financing and innovation. It combines academic rigor with industry insights, guest speakers, and applied projects that prepare students to raise capital, invest in, or lead high-growth biotech companies.

Instructor Info

Vinod Vathipadiekal, PhD

Chief Scientific Officer, Genetic Medicine, ProGenis Pharmaceuticals


Nicolas Labovitis, ALM

Chief Executive Officer, Ibex Finance, LLC


Meeting Info

Th 5:10pm - 7:10pm (8/31 - 12/19)

Participation Option: Online Asynchronous or Online Synchronous

In online asynchronous courses, you are not required to attend class at a particular time. Instead you can complete the course work on your own schedule each week.

Deadlines

Last day to register:

Prerequisites

BIOT E-100. While not required, prior advanced coursework in biotechnology, entrepreneurship, or finance (such as corporate finance or venture capital) will be helpful.

Notes

This course meets via web conference. Students may attend at the scheduled meeting time or watch recorded sessions asynchronously. Recorded sessions are typically available within a few hours of the end of class and no later than the following business day. See minimum technology requirements.

All Sections of this Course

CRN Section # Participation Option(s) Instructor Section Status Meets Term Dates
17558 1 Online Asynchronous, Online Synchronous Team Taught Open Th 5:10pm - 7:10pm
Aug 30 to Dec 18